GleamWall
中文EN

INBX Inhibrx Biosciences, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2007919 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY550.0%
TTM net income YoY-108.3%
TTM EPS YoY-108.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-10,386.5%
Net margin-10,773.5%
FCF margin-9,986.5%
EBITDA margin-10,195.5%

Returns

ROE-197.8%
ROA-85.6%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets94.5%
Debt / equity12.58x
Current ratio3.93x
Interest coverage-11.07x

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-6.3%
Payout ratio—
Capex / revenue2.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.30M$200,000
R&D expense$113.03M$203.74M
SG&A expense$23.30M$127.91M
Operating income-$135.03M-$331.45M
Interest expense$12.20M$13.49M
Pretax income-$140.05M$1.69B
Income tax$2,000$2,000
Net income-$140.06M$1.69B
EBITDA-$132.54M-$329.16M
EPS (basic)-9.04114.01
EPS (diluted)-9.04112.62
Weighted avg. shares (diluted)15.49M14.98M
Balance sheet
Cash & equivalents$124.22M$152.60M
Current assets$132.83M$160.40M
PP&E, net$3.73M$6.20M
Total assets$146.48M$180.77M
Current liabilities$33.80M$40.73M
Long-term debt$100.56M$0
Total debt$100.56M$0
Total liabilities$138.49M$47.18M
Shareholders' equity$7.99M$133.58M
Net debt-$23.66M-$152.60M
Shares outstanding14.58M14.48M
Cash flow statement
Operating cash flow-$129.79M-$194.41M
Capital expenditure$31,000$2.60M
Free cash flow-$129.82M-$197.01M
Investing cash flow-$28,000-$2.60M
Financing cash flow$101.45M$71.68M
Depreciation & amortization$2.48M$2.29M
Stock-based compensation$11.14M$58.52M

Free plan shows the latest 2 periods; Pro shows all 3 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.